Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
Mañosa
Míriam
M
Domènech
Eugeni
E
Marín
Laura
L
Olivé
Alejandro
A
Zabana
Yamile
Y
Cabré
Eduard
E
Gassull
Miquel A
MA
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab